Thanks to all the patients, caregivers, healthcare professionals and industry representatives who joined the inaugural IgG4ward! Jamboree! Zenas is proud to be among this community and support awareness for this chronic and serious fibroinflammatory disease. We appreciate Cathy Maxwell, MSN, RN, OCN, for sharing your perspective on the experience, as well as Shauna Quinn and Christine Chatas for representing Zenas. #IgG4RD #IgG4ward! #ZenasBio
Zenas BioPharma
生物技术研究
Waltham，MA 6,904 位关注者
Enabling patients with autoimmune diseases to reimagine life
关于我们
Zenas BioPharma (Nasdaq: ZBIO) is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative immunology-based therapies for patients in need. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s mechanism of action and chronic dosing regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease.
- 网站
-
https://zenasbio.com/
Zenas BioPharma的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Waltham，MA
- 类型
- 上市公司
- 领域
- Autoimmune Diseases和Immunology
地点
Zenas BioPharma员工
动态
-
Today we are pleased to announce that we completed targeted enrollment of our Phase 3 INDIGO trial, the largest clinical trial conducted for the treatment of patients with IgG4-RD. We also shared our Q3 2024 financial results and progress with our lead product candidate, obexelimab, for the treatment of autoimmune diseases. Read the press releases: https://lnkd.in/ecB4Vm3R ? https://lnkd.in/em6EN22Q ? #ZenasBio #IgG4RD #IgG4relateddisease #autoimmune #biotech
-
We look forward to participating in the?Guggenheim Partners?Inaugural Healthcare Innovation Conference and the?Jefferies?London Healthcare Conference in November, as well as the?Citi?2024 Global Healthcare Conference and?Evercore?ISI HealthCONx Conference in December to highlight?our company and lead product candidate, obexelimab,?for autoimmune diseases.?Get details here:?https://bit.ly/40IpeZA #ZenasBio #autoimmune #immunology
-
-
With Immunoglobulin G4-related disease (IgG4-RD) a recently described disease, IgG4ward’s patient, caregiver and healthcare provider support through community building, advocacy and education is so important. We are proud to sponsor and participate in the IgG4ward! Jamboree on November 9-10 in Washington, D.C. See you there! Learn more: https://igg4ward.org/ #IgG4wardJAM #IgG4RD #IgG4relateddisease #autoimmune #raredisease
-
-
We are pleased to welcome Jeff Held to Zenas BioPharma as our Chief Legal Officer! With his extensive and global life sciences expertise, Jeff will be vital in overseeing our legal and compliance functions as we advance our mission to become a leader in developing and commercializing transformative immunology-based therapies for patients in need. #ZenasBio #autoimmune #immunology #biotech
-
-
We are thrilled to share the news of our IPO and to be Nasdaq-listed as ZBIO! This financing allows Zenas Bio to continue to advance our mission to become a global leader in the development and commercialization of immunology-based therapies so that patients with autoimmune diseases can reimagine life. Thank you to everyone who has supported us! ? #IPO #Nasdaqlisted #ZenasBio #immunology #autoimmunediseases
-
-
Our recent #ZenasBio summer outing at Thompson Island was filled with fun! It was fantastic to spend time together and strengthen our connections outside of work. Special thanks to everyone who played a part in making our 2024 Summer Outing memorable!
-
-
Today we are excited to announce Orlando Oliveira as our Chief Commercial Officer! His significant global leadership delivering medicines to patients will be instrumental as the Zenas BioPharma team advances our immunology-based therapeutic candidates through the clinic. Read more, and welcome Orlando: https://lnkd.in/eR8HFGqi #autoimmune #immunology #biotech
-
-
We had a great time attending #EULAR2024 last week! Thank you to Mark Matijevic?and Rachel Kirk?for presenting on our clinical programs for #autoimmune disease, and to many of our other colleagues for hosting our booth. #igg4rd #SLE #wAIHA #MS